Nina M Muñoz1, Adeeb A Minhaj1, Kiersten L Maldonado2, Charles V Kingsley2, Andrea C Cortes1, Houra Taghavi2, Urszula Polak1, Jennifer M Mitchell3, Joe E Ensor4, James A Bankson2, Asif Rashid5, Rony Avritscher6. 1. Department of Interventional Radiology at The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States of America. 2. Department of Imaging Physics at The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States of America. 3. Department of Veterinary Medicine at The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States of America. 4. The Houston Methodist Research Institute, Houston, TX, United States of America. 5. Department of Pathology at The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States of America. 6. Department of Interventional Radiology at The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States of America. Electronic address: rony.avritscher@mdanderson.org.
Abstract
OBJECTIVES: To compare the accuracy of contrast-enhanced ultrasound (CEUS) and Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for the assessment of changes in tissue vascularization as result of sorafenib treatment in a rat model of hepatocellular carcinoma (HCC). METHODS: Male Buffalo rats with orthotopic liver tumors treated daily with 7.5 mg/kg sorafenib via oral gavage for 2 weeks (n = 9) were subject to DCE-MRI and CEUS 2 weeks after tumor implantation - right before treatment initiation - and also after treatment completion - right before tumor harvest. Untreated animals (n = 10) were used as control. Tumor tissue sections were stained for hematoxylin-eosin, pimonidazole, and CD34 for quantitative assessment of necrosis, hypoxia, and microvessel density (MVD), respectively. RESULTS: Of all the DCE-MRI parameters that were evaluated, only volume transfer constant (Ktrans) measurements were significantly lower in sorafenib-treated tumors (0.18 vs 0.33 min-1, p < 0.01), indicating a substantial decrease in vascular permeability caused by the therapy. This reduction was associated with decreased MVD (3.9 vs 10.8% CD34+ cells, p < 0.01), higher tumor necrosis (31.9 vs 21.8%, p < 0.001) and hypoxia (19.7 vs 10.5% pimonidazole binding, p < 0.01). Moreover, statistical analysis demonstrate significant correlation of DCE-MRI Ktrans with histopathologic tissue necrosis (r = -0.537, p < 0.05) and MVD (r = 0.599, p < 0.05). Interestingly, none of the CEUS measurements were significantly different between the control and treatment groups, and did not show statistical correlation with any of the histopathological parameters assessed (p > 0.05). CONCLUSIONS: Sorafenib-induced reduction in vascular permeability in this preclinical model of HCC is detected more accurately through DCE-MRI than CEUS, and DCE-MRI parameters strongly correlate with histopathological changes in tissue vascularization and tissue necrosis.
OBJECTIVES: To compare the accuracy of contrast-enhanced ultrasound (CEUS) and Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for the assessment of changes in tissue vascularization as result of sorafenib treatment in a rat model of hepatocellular carcinoma (HCC). METHODS: Male Buffalo rats with orthotopic liver tumors treated daily with 7.5 mg/kg sorafenib via oral gavage for 2 weeks (n = 9) were subject to DCE-MRI and CEUS 2 weeks after tumor implantation - right before treatment initiation - and also after treatment completion - right before tumor harvest. Untreated animals (n = 10) were used as control. Tumor tissue sections were stained for hematoxylin-eosin, pimonidazole, and CD34 for quantitative assessment of necrosis, hypoxia, and microvessel density (MVD), respectively. RESULTS: Of all the DCE-MRI parameters that were evaluated, only volume transfer constant (Ktrans) measurements were significantly lower in sorafenib-treated tumors (0.18 vs 0.33 min-1, p < 0.01), indicating a substantial decrease in vascular permeability caused by the therapy. This reduction was associated with decreased MVD (3.9 vs 10.8% CD34+ cells, p < 0.01), higher tumor necrosis (31.9 vs 21.8%, p < 0.001) and hypoxia (19.7 vs 10.5% pimonidazole binding, p < 0.01). Moreover, statistical analysis demonstrate significant correlation of DCE-MRI Ktrans with histopathologic tissue necrosis (r = -0.537, p < 0.05) and MVD (r = 0.599, p < 0.05). Interestingly, none of the CEUS measurements were significantly different between the control and treatment groups, and did not show statistical correlation with any of the histopathological parameters assessed (p > 0.05). CONCLUSIONS:Sorafenib-induced reduction in vascular permeability in this preclinical model of HCC is detected more accurately through DCE-MRI than CEUS, and DCE-MRI parameters strongly correlate with histopathological changes in tissue vascularization and tissue necrosis.
Authors: Julie Ouellette; Xavier Toussay; Cesar H Comin; Luciano da F Costa; Mirabelle Ho; María Lacalle-Aurioles; Moises Freitas-Andrade; Qing Yan Liu; Sonia Leclerc; Youlian Pan; Ziying Liu; Jean-François Thibodeau; Melissa Yin; Micael Carrier; Cameron J Morse; Peter Van Dyken; Christopher J Bergin; Sylvain Baillet; Christopher R Kennedy; Marie-Ève Tremblay; Yannick D Benoit; William L Stanford; Dylan Burger; Duncan J Stewart; Baptiste Lacoste Journal: Nat Neurosci Date: 2020-07-13 Impact factor: 24.884
Authors: Andrea C Cortes; Hideyuki Nishiofuku; Urszula Polak; Adeeb A Minhaj; Mirtha S Lopez; Kimihiko Kichikawa; Aliya Qayyum; Elizabeth M Whitley; Rony Avritscher Journal: Nanomedicine Date: 2021-09-24 Impact factor: 6.096
Authors: Marites P Melancon; Steven Yevich; Rony Avritscher; Adam Swigost; Linfeng Lu; Li Tian; Jossana A Damasco; Katherine Dixon; Andrea C Cortes; Nina M Munoz; Dong Liang; David Liu; Alda L Tam Journal: Drug Deliv Date: 2021-12 Impact factor: 6.419